SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS
December 08 2020 - 8:00AM
InvestorsHub NewsWire
SUNSHINE
BIOPHARMA ORDERS A NEW
BATCH OF Adva-27a FOR TESTING ON
TOPII
AMPLIFIED CANCERS
Montreal, Quebec, Canada
-- December 8, 2020 -- InvestorsHub NewsWire
-- Sunshine
Biopharma Inc. (OTC
PINK: "SBFM"), a pharmaceutical company
focused on the research, development and commercialization
of oncology
and antiviral drugs, today
announced that it has ordered a new batch of Adva-27a
from its
manufacturer in China. The material will be delivered
to the
laboratories of Sunshine Biopharma's drug development partner in Montreal
(Canada). Sunshine plans to use the
material to conduct testing on various types of cancer cells
that overproduce
Topoisomerase II (TopII). Following these cell
culture studies, Sunshine will
proceed to
performing studies on mice harboring tumors of
human origin with TopII amplification.
TopII
is
an
essential cell cycle enzyme that
is amplified in approximately 4% of all
human cancers.
"All cancer types that have
amplification of the Topoisomerase II gene are potential
new
targets for our
Adva-27a," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This
is an
additional application for our Adva-27a beyond the
original multidrug resistance indication," he added.
About
Sunshine Biopharma
In addition,
to working on the
development of a treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests
conducted to
date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug
Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University's
Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property
pertaining to Adva-27a.
Safe Harbor
Forward-Looking Statements
This
press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).
Actual
results and the timing of certain events could differ materially
from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed
from time to time in our filings with the SEC. Among other matters,
the Company may not be able to sustain growth or achieve
profitability based upon many factors including but not limited to
general stock market conditions. Reference is hereby made to
cautionary statements set forth in the Company's most recent SEC
filings. We have incurred and will continue to incur significant
expenses in our expansion of our existing as well as new service
lines noting there is no assurance that we will generate enough
revenues to offset those costs in both the near and long
term.
Additional
service offerings may expose us to additional legal and regulatory
costs and unknown exposure(s) based upon the various geopolitical
locations we will be providing services in, the impact of which
cannot be predicted at this time.
For
Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma
Inc.
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com